FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2565567265> ?p ?o ?g. }

• W2565567265 endingPage "2462" @default.
• W2565567265 startingPage "2462" @default.
• W2565567265 abstract "Abstract Introduction: The sialoadhesin receptor CD33 is a well-established target in the treatment of acute myeloid leukemia (AML). CD33 is expressed on leukemic blasts in AML and possibly also on leukemic stem cells in some patients (1). Thorium-227, an alpha-particle emitting radionuclide with a half-life of 18.7 days, is being studied for use as a possible cytotoxic agent. We have developed a novel Targeted Thorium Conjugate (TTC), comprising an anti-CD33 monoclonal antibody conjugated to a chelator for the efficient delivery of high-energy alpha-particles. We present data from in vitro cell cytotoxicity assays as well as biodistribution and efficacy data from preclinical animal models of AML. Experimental procedures: Antibody conjugates were prepared and labeled with 227Th at room temperature giving high radiochemical yields and purity. In vitro cell cytotoxicity experiments were carried out on HL-60 cells and the multi-drug resistant cell line KG-1 by measuring cell viability and monitoring apoptosis. In vivo efficacy and biodistribution were performed in a sub-cutaneous model of AML in athymic nude (nu/nu) mice using HL-60 cells. The 227Th-anti-CD33 conjugate was further tested in a disseminated model of AML using HL-60 cells, injected intravenously 5 days prior to treatment in CB.17 SCID mice with hind-leg paralysis as endpoint. Results: The 227Th-anti-CD33 conjugate was a potent and specific inducer of in vitro cell cytotoxicity independent of MDR-status. Mechanistic studies demonstrated cell arrest in G2 phase with cytotoxicity associated with apoptotic pathways. In vivo biodistribution in a sub-cutaneous model demonstrated a high tumor to blood ratio (TBR ∼ 6) at day 7 post injection based on measured 227Th-activity. Significant efficacy was achieved in two models of AML using human HL-60 cells. In athymic nude mice, a single injection of 227Th-anti-CD33 conjugate at 700 kBq/kg resulted in complete regression of established sub-cutaneous tumors. Importantly, no significant loss in body weight was observed during the course of the study, demonstrating that the dose was well tolerated. In parallel, statistically significant dose dependency of 227Th-anti-CD33 conjugate was demonstrated in a disseminated model of AML with median survival times (MST) of 90 days and 116 days for animals receiving 50 and 150 kBq/kg. Around 80% of animals dosed with either 2 × 150 or 1 × 300 kBq/kg where still alive at the end of the study with no gross pathological findings observed. Conclusions: The data presented are supportive of the further investigation of the 227Th-anti-CD33 conjugate for the treatment of AML. References: (1) Walter RB et al, Blood 2012, Vol 119, Number 26 (“Acute myeloid leukemia stem cells and CD33-targeted immunotherapy”) Citation Format: Urs B. Hagemann, Joergen Borrebaek, Adam O'Shea, Ellen Wang, Katrine Wickstroem, Roger M. Bjerke, Jenny Karlsson, Olav B. Ryan, Alan Cuthbertson. In Vivo efficacy of a novel anti-CD33 targeted thorium conjugate (TTC) in mouse models of acute myeloid leukemia (AML). [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2462. doi:10.1158/1538-7445.AM2015-2462" @default.
• W2565567265 created "2017-01-06" @default.
• W2565567265 creator A5021186575 @default.
• W2565567265 creator A5037599842 @default.
• W2565567265 creator A5046918313 @default.
• W2565567265 creator A5063128206 @default.
• W2565567265 creator A5072394114 @default.
• W2565567265 creator A5075470154 @default.
• W2565567265 creator A5088981442 @default.
• W2565567265 creator A5090746486 @default.
• W2565567265 creator A5091507521 @default.
• W2565567265 date "2015-08-01" @default.
• W2565567265 modified "2023-09-24" @default.
• W2565567265 title "Abstract 2462:In Vivoefficacy of a novel anti-CD33 targeted thorium conjugate (TTC) in mouse models of acute myeloid leukemia (AML)" @default.
• W2565567265 doi "https://doi.org/10.1158/1538-7445.am2015-2462" @default.
• W2565567265 hasPublicationYear "2015" @default.
• W2565567265 type Work @default.
• W2565567265 sameAs 2565567265 @default.
• W2565567265 citedByCount "3" @default.
• W2565567265 countsByYear W25655672652019 @default.
• W2565567265 countsByYear W25655672652022 @default.
• W2565567265 crossrefType "journal-article" @default.
• W2565567265 hasAuthorship W2565567265A5021186575 @default.
• W2565567265 hasAuthorship W2565567265A5037599842 @default.
• W2565567265 hasAuthorship W2565567265A5046918313 @default.
• W2565567265 hasAuthorship W2565567265A5063128206 @default.
• W2565567265 hasAuthorship W2565567265A5072394114 @default.
• W2565567265 hasAuthorship W2565567265A5075470154 @default.
• W2565567265 hasAuthorship W2565567265A5088981442 @default.
• W2565567265 hasAuthorship W2565567265A5090746486 @default.
• W2565567265 hasAuthorship W2565567265A5091507521 @default.
• W2565567265 hasConcept C10205521 @default.
• W2565567265 hasConcept C109316439 @default.
• W2565567265 hasConcept C134306372 @default.
• W2565567265 hasConcept C154317977 @default.
• W2565567265 hasConcept C159654299 @default.
• W2565567265 hasConcept C176290653 @default.
• W2565567265 hasConcept C185592680 @default.
• W2565567265 hasConcept C197336794 @default.
• W2565567265 hasConcept C202751555 @default.
• W2565567265 hasConcept C203014093 @default.
• W2565567265 hasConcept C2777807558 @default.
• W2565567265 hasConcept C2778461978 @default.
• W2565567265 hasConcept C2778729363 @default.
• W2565567265 hasConcept C28328180 @default.
• W2565567265 hasConcept C33923547 @default.
• W2565567265 hasConcept C502942594 @default.
• W2565567265 hasConcept C542903549 @default.
• W2565567265 hasConcept C55493867 @default.
• W2565567265 hasConcept C71924100 @default.
• W2565567265 hasConcept C86803240 @default.
• W2565567265 hasConcept C95444343 @default.
• W2565567265 hasConceptScore W2565567265C10205521 @default.
• W2565567265 hasConceptScore W2565567265C109316439 @default.
• W2565567265 hasConceptScore W2565567265C134306372 @default.
• W2565567265 hasConceptScore W2565567265C154317977 @default.
• W2565567265 hasConceptScore W2565567265C159654299 @default.
• W2565567265 hasConceptScore W2565567265C176290653 @default.
• W2565567265 hasConceptScore W2565567265C185592680 @default.
• W2565567265 hasConceptScore W2565567265C197336794 @default.
• W2565567265 hasConceptScore W2565567265C202751555 @default.
• W2565567265 hasConceptScore W2565567265C203014093 @default.
• W2565567265 hasConceptScore W2565567265C2777807558 @default.
• W2565567265 hasConceptScore W2565567265C2778461978 @default.
• W2565567265 hasConceptScore W2565567265C2778729363 @default.
• W2565567265 hasConceptScore W2565567265C28328180 @default.
• W2565567265 hasConceptScore W2565567265C33923547 @default.
• W2565567265 hasConceptScore W2565567265C502942594 @default.
• W2565567265 hasConceptScore W2565567265C542903549 @default.
• W2565567265 hasConceptScore W2565567265C55493867 @default.
• W2565567265 hasConceptScore W2565567265C71924100 @default.
• W2565567265 hasConceptScore W2565567265C86803240 @default.
• W2565567265 hasConceptScore W2565567265C95444343 @default.
• W2565567265 hasIssue "15_Supplement" @default.
• W2565567265 hasLocation W25655672651 @default.
• W2565567265 hasOpenAccess W2565567265 @default.
• W2565567265 hasPrimaryLocation W25655672651 @default.
• W2565567265 hasRelatedWork W1971628265 @default.
• W2565567265 hasRelatedWork W2007464029 @default.
• W2565567265 hasRelatedWork W2024199689 @default.
• W2565567265 hasRelatedWork W2071664329 @default.
• W2565567265 hasRelatedWork W2119737712 @default.
• W2565567265 hasRelatedWork W2171169115 @default.
• W2565567265 hasRelatedWork W2363271996 @default.
• W2565567265 hasRelatedWork W2368697212 @default.
• W2565567265 hasRelatedWork W2374478607 @default.
• W2565567265 hasRelatedWork W2383507869 @default.
• W2565567265 hasVolume "75" @default.
• W2565567265 isParatext "false" @default.
• W2565567265 isRetracted "false" @default.
• W2565567265 magId "2565567265" @default.
• W2565567265 workType "article" @default.